Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer.
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer.
复制标题
DOI：
10.1097/ppo.0000000000000615
复制
发表时间：
2022-09-01
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
头颈部鳞状细胞癌（HNSCC）是全球第六大流行癌症，每年新发病例60万例。尽管在手术、化疗和放疗方面取得了进展，但在过去的几十年里，HNSCC患者的总生存率并没有显著提高。FGF/FGFR基因组改变经常在HNSCC中检测到，包括扩增、激活突变和染色体重排。其中，FGFR 1扩增、FGF扩增和FGFR 3突变最为普遍。此外，在大多数HNSCC中也观察到FGF/FGFR表达。然而，FGF/FGFR异常的预后价值仍不清楚，特别是对于基因扩增和过表达。尽管如此，FGF/FGFR一直是HNSCC治疗的有希望的靶点，最近的临床前研究证明了涉及FGFR抑制剂的联合治疗方案对HNSCC的潜力。因此，目前有许多FGFR抑制剂在临床试验中用于治疗头颈癌。
Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most prevalent cancer worldwide, with an annual incidence of 600,000 new cases. Despite of advances in surgery, chemotherapy, and radiotherapy, the overall survival for HNSCC patients hasn’t been significantly improved over the past several decades. FGF/FGFR genomic alterations are frequently detected in HNSCC, including amplification, activating mutation, and chromosomal rearrangement. Among them, FGFR1 amplification, FGF amplifications, and FGFR3 mutations are the most prevalent. In addition, FGF/FGFR expression has also been observed in the majority of HNSCC. However, the prognostic value of FGF/FGFR aberrations remains unclear, especially for gene amplification and overexpression. Nonetheless, FGF/FGFR has been a promising target for HNSCC treatment, and recent preclinical studies demonstrate the potential of the combination treatment regimens involving FGFR inhibitors on HNSCC. Therefore, there are a number of FGFR inhibitors currently in clinical trials for the treatment of head and neck cancers.
影响因子：
5.2
作者：
Taghizadeh H;Mader RM;Müllauer L;Fuereder T;Kautzky-Willer A;Prager GW
通讯作者：
Prager GW
影响因子：
1.9
作者：
Basura GJ;Smith JD;Ellsperman S;Bhangale A;Brenner JC
通讯作者：
Brenner JC